In: NEOPLASMA, vol. 61, no. 5
X. Chen - Y. Liu - H.-W. Yang - S. Zhou - C. Cheng - M.-W. Zheng - L. Zhong - X.-Y. Fu - Y.-L. Pan - S. Ma - Y. Tang - Y.-Z. Chen - L.-L. Li - S.-Y. Yang
Detaily:
Rok, strany: 2014, 514 - 522
O článku:
Colorectal cancer (CRC) is the third common cancer and most of the chemotherapies of CRC currently used often suffer limited efficacy and large side effects. Targeted small-molecule by anti-tumor drugs are thought a promising strategy for improving the efficacy and reducing the side effects. In this investigation, we report a novel multikinase inhibitor, termed SKLB-287, which was discovered by us recently. SKLB-287 could efficiently inhibit the activation of endothelial growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2). It displayed very good anti-proliferative activity against LoVo CRC cells and considerable antiangiogenic potency in transgenic zebrafish embryos. Oral administration of SKLB-287 resulted in dose-dependent suppression of tumor growth in LoVo xenograft mouse model. Immunohistochemistry was adopted to examine the in vivo anti-tumor mechanism of action of SKLB-287. Keywords: SKLB-287, EGFR, antiangiogenesis, colorectal cancer
Ako citovať:
ISO 690:
Chen, X., Liu, Y., Yang, H., Zhou, S., Cheng, C., Zheng, M., Zhong, L., Fu, X., Pan, Y., Ma, S., Tang, Y., Chen, Y., Li, L., Yang, S. 2014. SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model. In NEOPLASMA, vol. 61, no.5, pp. 514-522. 0028-2685.
APA:
Chen, X., Liu, Y., Yang, H., Zhou, S., Cheng, C., Zheng, M., Zhong, L., Fu, X., Pan, Y., Ma, S., Tang, Y., Chen, Y., Li, L., Yang, S. (2014). SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model. NEOPLASMA, 61(5), 514-522. 0028-2685.